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LETTER TO THE EDITOR
Drug response proﬁling can predict response to ponatinib in a
patient with t(1;9)(q24;q34)-associated B-cell acute
lymphoblastic leukemia
Blood Cancer Journal (2015) 5, e292; doi:10.1038/bcj.2015.13;
published online 13 March 2015
Tyrosine kinase inhibitor (TKI)-based targeted therapy has
signiﬁcantly modiﬁed the outcome for patients with chronic
myeloid leukemia (CML) in chronic phase. However, resistance
remains a major concern in blastic phase of CML and in
Philadelphia chromosome positive B-cell acute lymphoblastic
leukemia (Ph+ B-ALL). Second- and third-generation TKIs have
been developed to overcome resistance to ﬁrst generation drugs,
but selecting the appropriate drug has become a challenge.
Various tests are available to determine a patient’s disease status
in CML including the mechanisms of resistance when involved,
but clinical experience is limited in ALL, especially those with
poorly deﬁned ABL1 rearrangements. Here, we report a case of
ALL associated with a t(1;9)(q24;q34) RCSD1-ABL1 rearrangement.
We show how ex vivo drug response proﬁling (DRP) may help
choose among various therapeutic options.
A 26 year-old female presented in September 2012 with
fatigue and antibiotic-resistant ENT infection. Blood counts
showed WBC 26 g/l with 84% blasts on peripheral blood. Marrow
smear examination conﬁrmed the diagnosis of ALL with 86%
blasts. Flow cytometry was consistent with common ALL with
expression of CD79a+, CD19+, CD10+ and weak expression of
CD20. Positivity of CD33 was also noticed. Cytogenetics showed
an uncommon t(1;9)(q24;q34) and involvement of ABL1 was
conﬁrmed by ﬂuorescence in situ hybridization FISH (not
shown). In agreement with the previous characterization of
t(1;9)(q24;q34),1–3 Real time-PCR analysis from leukemic cells
showed the expression of the RCSD1-ABL1 gene fusion
(Supplementary Material 1a), and sequencing of the PCR
products showed that RCSD1 exon 3 was fused to ABL1 exon 4
(Supplementary Material 1b).
On the basis of these results and the cases previously reported2
the patient was treated with steroids, vincristine and dasatinib. In
October 2012, the patient reached morphologic complete
remission (CR) and FISH analysis showed a 2% residual disease
on 500 nuclei. She received consolidation based on hyperCVAD
dasatinib strategy and 0.2% residual disease by FISH was achieved
after two cycles of consolidation. A matched-sibling hematopoie-
tic stem cell (HSC) transplantation with reduced toxicity con-
ditioning was performed in February 2013. The patient relapsed
(R1) in December 2013. Clonal evolution was observed with newly
appearing t(6;13) (35% of mitosis) and t(11;15) (8% of mitosis) in
addition to the t(1;9). She was treated with intensive chemother-
apy (mitoxantrone, high dose cytarabine, etoposide, dexametha-
sone and asparaginase). She achieved a second CR in January
2014, received consolidation chemotherapy but relapsed (R2) in
April 2014 with 10% marrow blasts.
An ex vivo functional evaluation of the DRP of the
patient leukemic blasts at R1 was undertaken using our DRP
platform4 with a speciﬁc focus on TKIs. Each drug was
tested over a 1000-fold concentration range, allowing the
establishment of dose-response curves and the identiﬁcation of
half-maximal effective concentration responses (Figures 1a, b
and Supplementary Material 2). Resistance and/or low response
to some TKIs were observed such as dasatinib or nilotinib
(EC504 or ﬃ20 μM), whereas measurable responses to others
were noted, notably to ponatinib (EC50 = 0.8 μM). This differential
response to ponatinib as compared with dasatinib was con-
ﬁrmed in a secondary dose-response study (Figure 1c), which
showed comparable drug sensitive proﬁle for samples of the
patient obtained at diagnosis and at R1. Exon sequencing did not
show any ABL1 mutation that could account for the differential
response to the two drugs. A total of 419 other genes were
studied (Supplementary material 3); none was differentially
mutated.
In parallel, the samples of the patient collected at diagnosis and
at R1 were grafted into NSG mice. Engraftment was successful for
both samples, starting at day 57 post-injection for samples
obtained at R1 (74.7 ± 16.1 blasts/μl of blood) and at day 72 post-
injection for samples obtained at diagnosis (11.4 ± 3 blasts/μl of
blood, as compared with 146 ± 58.6 blasts for samples obtained at
R1), and both progressed then after (Figure 1d). Genomic proﬁles
of leukemic cells from both the patient and the cognate
transplants were established by using array-comparative genomic
hybridizations. They were similar (Supplementary Materials 4a vs
4c and 4b vs 4d, respectively) indicating that the generated animal
models reﬂected the disease. Interestingly, 6p23-p24 and 13q14.2-
q14.3 regional losses occurred in leukemic cells from both the
patients at R1 and the corresponding cognate transplants
(Supplementary Materials 4b and 4d, respectively) suggesting a
genomic evolution of the disease. Differences of gene copy
number variations in these chromosomal regions are illustrated for
the four samples (Supplementary Materials 4e and 4f). They
targeted several genes including potential candidates such as
JARID2 (on 6p22.3), miRNA15 and miRNA16 (on 13q14.2, arrows).
These losses are likely to be associated with the t(6;13)(p23;q14)
event characterized in leukemic cells from the patient at R1
(Supplementary Material 4g).
One mouse from the group of animals transplanted with the
relapse sample was killed at day 106 and bone marrow cells were
transferred to secondary recipients (106 cells per mice). Fifty days
after engraftment, blasts were counted and animals were
homogeneously distributed into three groups receiving diluent
(dimethyl sulfoxide), dasatinib (25 mg/Kg, 5 days out of 7 for
4 weeks) or ponatinib (30 mg/Kg, 4 days out of 7 for 4 weeks) as
described.5 As shown in Figure 1e, at days 14 and 28 after
initiation of treatment, blast counts were determined, showing
reduced progression of the disease in dasatinib-treated animals
(96 ± 41 blasts/μl of blood) as compared with control animals
(344 ± 63 blasts/μl of blood) at day 28 (Po0.0001), and a
signiﬁcant regression in ponatinib-treated animals, both at day
14 (49 ± 17 blasts/μl of blood vs 296 ± 169 blasts/μl of blood in the
control group, Po0.0001) and day 28 (19 ± 7 blasts/μl of blood vs
344 ± 63 blasts/μl of blood, Po0.0001). On the basis of this, the
patient was started on treatment with ponatinib monotherapy
(45 mg/day) in May 2014 and achieved a CR2. She received a
second HSC transplant from a HLA-haplo-identical donor in July
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Figure 1. Ex vivo DRP Identiﬁcation and in vivo validation of a t(1;9)(q24;q34) RCSD1-ABL1 bearing patient sensitivity to ponatinib. (a) Ficoll-
puriﬁed blood cells obtained from the patient at relapse (April 2014) were exposed for 48 h to varying concentrations of the indicated TKIs,
and cell viability was assessed using CellTiter-Glo luminescent assay (Promega, Charbonnières les Bains, France). The data are presented as
percent viability after normalization to negative control (dimethyl sulfoxide only). (b) Effective half-maximal concentration values (EC50)
deduced from the dose-response curves obtained in duplicate from two distinct drug testing plates (plate #1 and plate #2) are shown. (c) As in
a, except that Ficoll-puriﬁed blood cells obtained from the patient at diagnosis (September 2012) and at relapse (April 2014) were exposed for
48 h to varying concentrations of dasatinib and ponatinib. (d) Ficoll-puriﬁed blood cells obtained from the patient at diagnosis (September
2012) and at relapse (April 2014) were inoculated in the tail vein of NSG mice and the presence of human B-ALL blast cells in peripheral blood
obtained by retro-orbital bleeding was determined by ﬂow cytometry at different time points. Results are presented as the number of human
CD45 positive cells per μl of mice blood (mean± s.e.m., 4 animals per group). (e) Secondary transplantation was conducted by injecting bone
marrow cells of primary transplanted mice from d in new NSG recepients. At day 50 after secondary transplantation, human blasts present in
mice blood were determined to homogeneously distribute recepient mice into three groups receiving vehicle, dasatinib (25mg/kg, po) or
ponatinib (30mg/kg). Results are presented as the number of human CD45 positive cells per μl of mice blood as determined by Flow
cytometry at day 14 and day 28 after initiation of treatment (mean± s.e.m., 8 animals per group). The data were analyzed with a one-way
analysis of variance test (GraphPad Prism, GraphPad, La Jolla, CA, USA) and each group was further compared with the vehicle control group
for statistical signiﬁcance using Dunnett multiple comparison test. ***Po0.0001.
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2014 but relapsed at day 77 post transplantation with 12% BM
blasts. Ponatinib was restarted at this time. BM smear at day 92
showed 4% blasts. Signs of severe graft versus host disease were
present at this time. The patient died of a septic shock
2 weeks later.
This study illustrates how DRP may help select an appropriate
disease-adapted TKI, including consideration of treatment
changes, especially in case of rare and poorly deﬁned leukemia
such as RCSD1-ABL1 B-cell ALL. It illustrates the potential of DRP to
predict treatment effects. Ex vivo testing was indeed conﬁrmed by
in vivo experiments using the patient’s leukemic cells transplanted
into NSG mice. In addition, clinical activity observed with
ponatinib monotherapy that was offered to the patient after her
second relapse on the basis of DRP ultimately conﬁrmed the
clinical relevance of the test.
To our knowledge, this is the ﬁrst report of ponatinib successful
treatment of a t(1;9)(q24 ;q34) B-cell ALL. The superior efﬁcacy of
ponatinib as compared with dasatinib on the patient’s leukemia
cells, both ex vivo and in our xenotransplantation model, was
unexpected, based on the previous knowledge. Ponatinib is a
third-generation TKI inhibitor designed to target the most
frequent imatinib resistance-associated mutations in CML (such
as the T315I substitution).6 In vitro, as compared with dasatinib,
ponatinib exhibits signiﬁcant superior inhibitory activity against
mutated forms of BCR-ABL1, but is rather similar in efﬁcacy against
wild-type BCR-ABL1.7,8 The differential response of the patient’s
leukemia cells to dasatinib as compared with ponatinib in our case
was not explained by the presence of mutation(s) in ABL1 coding
sequences including T315I mutation, and is thus likely the result of
either the distinct signaling capability of RCSD1-ABL1,3 the
broad spectrum of ponatinib targets and/or the intrinsic spatial
adaptability of the inhibitor to bind different conformational states
of the kinase.7,8 Indeed, the RCSD1-ABL1 fusion contains only a
truncated ABL1 protein starting from the exon 4-encoded region,
and thus results in a fusion protein that lacks the SH3 regulatory
module and retains only part of the SH2 domain, which is involved
in the regulation of the kinase activity of BCR-ABL1.9 This
difference in structure may differentially impact dasatinib and
ponatinib efﬁcacy in contacting the active site of the ABL1 kinase.
Current molecular studies are undertaken to study these
hypothesis. Interestingly, ponatinib anti-leukemic activity was
not affected by the occurrence of t(6;13) and t(11;15) at relapse.
More generally, this report, together with others10,11 suggest that
precision medicine may be better based on both genomic data and
drug response (including ex vivo) data than on only one of these.
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